PAVmed Stock Based Compensation To Revenue from 2010 to 2024

PAVM Stock  USD 0.97  0.03  3.19%   
PAVmed Stock Based Compensation To Revenue yearly trend continues to be very stable with very little volatility. Stock Based Compensation To Revenue is likely to drop to 4.32. Stock Based Compensation To Revenue is a metric that compares the total value of stock-based compensation granted by PAVmed Inc to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. View All Fundamentals
 
Stock Based Compensation To Revenue  
First Reported
2010-12-31
Previous Quarter
4.54282219
Current Value
4.32
Quarterly Volatility
11.10555297
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 559.5 K or Selling General Administrative of 32.5 M, as well as many indicators such as Price To Sales Ratio of 11.54, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Valuation or Volatility modules.
  
Check out the analysis of PAVmed Correlation against competitors.

Latest PAVmed's Stock Based Compensation To Revenue Growth Pattern

Below is the plot of the Stock Based Compensation To Revenue of PAVmed Inc over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. PAVmed's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed's overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation To Revenue10 Years Trend
Slightly volatile
   Stock Based Compensation To Revenue   
       Timeline  

PAVmed Stock Based Compensation To Revenue Regression Statistics

Arithmetic Mean28.06
Geometric Mean24.12
Coefficient Of Variation39.58
Mean Deviation6.30
Median30.02
Standard Deviation11.11
Sample Variance123.33
Range47.489
R-Value(0.32)
Mean Square Error119.06
R-Squared0.10
Significance0.24
Slope(0.80)
Total Sum of Squares1,727

PAVmed Stock Based Compensation To Revenue History

2024 4.32
2023 4.54
2022 51.81

About PAVmed Financial Statements

PAVmed investors utilize fundamental indicators, such as Stock Based Compensation To Revenue, to predict how PAVmed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Stock Based Compensation To Revenue 4.54  4.32 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether PAVmed Inc is a strong investment it is important to analyze PAVmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PAVmed's future performance. For an informed investment choice regarding PAVmed Stock, refer to the following important reports:
Check out the analysis of PAVmed Correlation against competitors.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.14)
Revenue Per Share
0.459
Quarterly Revenue Growth
4.898
Return On Assets
(0.80)
Return On Equity
(13.58)
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.